A randomized, double-blind, placebo-controlled study using the standardized Psoriasis Area and Severity Index (PASI) to evaluate the efficacy and safety of oral-PUVA in patients with chronic plaque psoriasis - 21/08/11
Shahrad Behnam, BS, John Y. Koo, MD, Arianne Chavez-Frazier, MD, Psoriasis Treatment Center, University of California San Francisco, San Francisco, CA, United States; Greg Kricorian, MD, Valeant Pharmaceuticals International, Costa Mesa, CA, United States
Le texte complet de cet article est disponible en PDF. P2708 Shahrad Behnam and Dr. Chavez-Frazier have no conflicts of interest. Dr. Koo has been a clinical researcher, consultant, and speaker for Valeant (ICN), Allergan, Amgen, Biogen, Bristol-Myers Squibb, Centacor, Connetics, Elan, Fujisawa, Galderma, Genentech, GlaxoSmithKlein, Novartis, and Roche. Dr. Kricorian is employed by Valeant Pharmaceuticals International. 100% sponsored by Valeant Pharmaceuticals International, formerly known as ICN Pharmaceuticals |
Vol 52 - N° 3S
P. P173 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?